Agoracom Blog Home

Posts Tagged ‘AI’

Predictmedix’s Progress Paves the Way: Navigating Industry Success with Groundbreaking Health Innovations

Posted by Brittany McNabb at 10:06 AM on Friday, November 17th, 2023

In the fast-evolving landscape of health and safety, Predictmedix emerges as a beacon of innovation with its revolutionary Safe Entry Stations. As industries worldwide seek cutting-edge solutions, Predictmedix’s Safe Entry Stations are not only different; they are setting a new standard. This article delves into the unique features that set these stations apart and explores the notable companies embracing this transformative technology.

Revolutionizing Entry Protocols:

Predictmedix’s Safe Entry Stations go beyond traditional entry protocols. Unlike standard screening processes, these stations employ advanced artificial intelligence (AI) to conduct rapid, non-invasive health assessments. The technology ensures a swift yet comprehensive analysis, redefining how entry points are managed in various industries.

Differentiators that Matter:

What sets Predictmedix’s Safe Entry Stations apart are their multifaceted capabilities. From face detection and SOP violation detection to body temperature measurement, heart rate monitoring, and even assessing blood pressure, these stations offer a holistic health screening experience. The integration of these features positions Predictmedix as a leader in providing comprehensive health and safety solutions.

Companies Embracing the Future:

Notable industry leaders are recognizing the transformative potential of Predictmedix’s Safe Entry Stations. Companies across sectors, from healthcare to education, manufacturing, and more, are integrating these stations into their daily operations. This broad acceptance is a testament to the stations’ adaptability and effectiveness in diverse environments.

Healthcare Institutions Leading the Way:

In the healthcare sector, where precision and efficiency are paramount, Predictmedix’s Safe Entry Stations find prominent application. Hospitals, clinics, and medical facilities are leveraging this technology to ensure the safety of both staff and patients. The stations’ accuracy in detecting vital signs, including potential COVID-19 symptoms, positions them as a crucial asset in the ongoing battle against the pandemic.

Ensuring Safe Learning Environments:

Predictmedix’s Safe Entry Stations are making waves in the education sector. Schools, colleges, and vocational training institutes are embracing this technology to create safe learning environments. The stations not only enhance safety but also provide a real-world application of AI, offering an educational experience beyond textbooks.

Manufacturing and Corporate Spaces:

Beyond healthcare and education, manufacturing and corporate sectors are integrating Predictmedix’s Safe Entry Stations into their facilities. These stations contribute to creating secure workplaces by identifying potential health risks among employees, ensuring a proactive approach to employee well-being and safety.

Revolutionizing Health Screening with 95% Accuracy:

The recent clinical validation breakthrough, achieving a remarkable 95% accuracy, is a testament to Predictmedix’s dedication to excellence. This milestone propels the company to the forefront of health screening, introducing a level of precision that redefines the standards in the industry.

Showcasing Revolutionary Health and Safety Solutions:

Predictmedix doesn’t merely embrace industry trends; it showcases revolutionary solutions. At the D-30 event in New Delhi, the company presented groundbreaking health and safety solutions, emphasizing its commitment to fostering a global culture of well-being and safety.

Revolutionizing the Global Fight Against Drug Addiction:

Predictmedix’s cutting-edge screening technology emerges as a game-changer in the fight against drug addiction. Beyond identification, the technology’s utility extends to managing patient health, providing a comprehensive solution for a safer, drug-free world.

Real-world Impact:

The real-world impact of Predictmedix’s Safe Entry Stations is tangible. Beyond the buzz of innovation, these stations are actively reshaping how companies manage health and safety, ensuring compliance with protocols, and fostering a culture of well-being.

Conclusion:

In conclusion, Predictmedix’s Safe Entry Stations represent a paradigm shift in health and safety solutions. Their widespread adoption across diverse industries underscores their versatility and effectiveness. As companies worldwide seek to redefine their approach to health screening, Predictmedix stands at the forefront, offering a transformative solution that goes beyond compliance—it pioneers a new era in health and safety. Investors keen on companies leading the charge in innovative health technologies should keep a close eye on Predictmedix and its pioneering Safe Entry Stations.

 

YOUR NEXT STEPS

Visit $PMED HUB On AGORACOM: https://agoracom.com/ir/Predictmedixhttps 

Visit $PMED 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Predictmedix/profile

Visit $PMED Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Predictmedix/forums/discussion

Watch $PMED Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions

Predictmedix AI Revolutionizes Health Screening with 95% Accuracy: A Breakthrough Clinical Validation

Posted by Brittany McNabb at 7:54 AM on Tuesday, November 14th, 2023

In a groundbreaking move toward advancing health screening technology, Predictmedix AI Inc. has achieved a significant milestone with a successful clinical validation at the University of Raharja, Indonesia. This accomplishment, marked by a remarkable 95% accuracy in vital sign detection, underscores Predictmedix’s commitment to prioritizing well-being through cutting-edge artificial intelligence (AI).

Predictmedix AI, a leader in rapid health screening solutions, has a rich history of leveraging AI to redefine safety culture and enhance the physical and mental well-being of individuals. This collaborative effort with the University of Raharja is a testament to the company’s dedication to innovation and its mission to foster a “Fit for Duty” culture.

Key Highlights and Advantages:

The clinical study aimed to develop non-invasive AI-based software capturing vital signs, including heart rate, respiration rate, height, body temperature, and blood pressure.

Notably, the solution prioritizes privacy by avoiding recognizable facial images while ensuring accurate and consistent vital sign readings.

Key features include face detection, SOP violation detection, body temperature detection, heart rate monitoring, respiration rate monitoring, SpO2 measurement, height assessment, and blood pressure measurement.

Potential Impact and Significance:

The clinical validation, with an impressive 95% accuracy across critical parameters, is a monumental achievement. Predictmedix AI’s solution holds the potential to revolutionize health screening, creating safer and more efficient workplaces globally. The iterative refinements in the AI algorithms ensure continuous improvement, with an accuracy range between 90% and 99% for all vital signs.

Expert Opinions and Analysis:

Dr. Rahul Kushwah, Chief Operating Officer of Predictmedix AI, expressed the significance of this milestone, stating, “The accuracy and maturity of our AI solution, especially in vital sign screening, are truly rewarding. We eagerly anticipate exploring broader applications to benefit society.” Raharja University endorses Predictmedix’s Safe Entry Station solution, highlighting its effectiveness in non-invasive patient screening for various conditions.

Challenges and Considerations:

While the clinical validation marks a substantial achievement, potential challenges in adoption and implementation may arise. Predictmedix AI is well-prepared to address these challenges, ensuring the continuous refinement and reliability of their AI solution.

Predictmedix AI’s breakthrough in achieving 95% accuracy in vital sign detection heralds a new era in health screening technology. This accomplishment reinforces the company’s position as a leader in the field and sets the stage for broader applications that can benefit society at large. As Predictmedix continues to innovate, its commitment to fostering a safer and healthier global community remains unwavering.

View original release: https://predictmedix.com/predictmedix-ai-announces-successful-clinical-validation-at-the-university-of-raharja-indonesia-demonstrating-95-accuracy-in-vital-sign-detection/ 

 

Tech2heal Partners with Leading Virtual Occupational Health Clinics in a Stride Towards Mental Health and Sleep Disorder Prevention

Posted by Brittany McNabb at 8:51 AM on Thursday, November 9th, 2023

 

AI/ML Innovations Inc. continues to make waves in the realm of Artificial Intelligence/Machine Learning technologies. Their subsidiary, Tech2heal, has recently entered a strategic partnership with a leading French company specializing in virtual occupational health clinics. This alliance aims to address critical aspects of employee well-being, with a particular focus on mental health and sleep disorders. The implications of this partnership extend beyond mere business collaboration; it heralds a profound shift in the approach to mental health and sleep disorders in the workplace, a topic of growing importance in the modern professional landscape.

A Pioneering Approach to Workplace Well-Being

Tech2heal’s venture into the realm of mental health and sleep disorder prevention represents a pioneering approach to addressing the well-being of employees. By joining forces with a prominent French health service provider, Tech2heal’s versatile AI-powered clinical care platform, Alakin, is poised to play a pivotal role in redefining how companies approach these critical issues. This innovative collaboration is fueled by the desire to enhance employee well-being in an ever-evolving workplace environment.

The Power of Tech2heal’s Alakin Platform

The key to this transformative partnership is Tech2heal’s Alakin platform, a powerful AI-driven solution known for its adaptability. Alakin’s capacity to create highly customizable, hybrid care pathways provides a strong foundation for addressing the unique needs of each corporate client. By streamlining care pathways and offering a user-friendly interface, Alakin ensures a seamless experience for both patients and healthcare practitioners.

Accelerating Market Adoption

The alliance between Tech2heal and the French health service provider is set to expedite the introduction of innovative employee risk prevention solutions to the market. This acceleration is a response to the growing demand for mental health and sleep disorder solutions, highlighting the timeliness and relevance of this partnership.

A Comprehensive Approach

The collaboration equips the Partner with a comprehensive suite of healthcare tools, addressing the needs of patients and healthcare practitioners. This holistic approach underscores the commitment to considering every facet of employee well-being, from mental health to sleep disorders.

Shifting Priorities in Workplace Health

Paul Duffy, CEO of AIML, emphasizes that mental health issues and sleep disorders have a substantial impact on employee productivity and organizational costs. This alliance signifies a shift in attitudes towards prioritizing the well-being of employees and marks a positive step towards proactive management of mental health and sleep disorders in the workplace.

The partnership between Tech2heal and the undisclosed French health service provider is more than a business collaboration; it is a symbol of changing attitudes and priorities in the modern workplace. As mental health and sleep disorders take center stage in discussions of employee well-being, the alliance sets a transformative precedent. Tech2heal’s Alakin platform and the Partner’s innovative solutions combine to create a powerful force dedicated to enhancing the lives of employees. This visionary approach to workplace well-being exemplifies the company’s commitment to using AI-driven technologies to address societal needs, with a keen focus on improving the health and well-being of individuals in the professional world.

As AI/ML Innovations Inc. continues to make strides in the world of Artificial Intelligence and Machine Learning, their foray into healthcare management solutions reflects a broader trend of technology-driven well-being and precision support. This partnership exemplifies a new era where the health of employees takes center stage in corporate priorities. It’s a welcome shift, and one that could have far-reaching implications for the future of the workplace and the well-being of its employees.

View original release: https://www.accesswire.com/801457/aiml-innovations-incs-subsidiary-announces-strategic-partnership-with-a-leader-in-virtual-occupational-health-clinics

Tech2Heal Chosen for International Clinical Trial Funded by European Commission

Posted by Brittany McNabb at 8:40 AM on Wednesday, October 18th, 2023

 

Tech2Heal SAS, a subsidiary of AI/ML Innovations Inc., has marked a significant milestone by securing its second clinical trial contract for the “My Health Friend” project. This groundbreaking initiative, a collaborative effort between French and Italian University Hospitals, is funded by a European Commission fund. The project aims to revolutionize preventative healthcare, targeting populations in remote areas with limited access to in-person healthcare services.

At the core of this pioneering endeavor is Tech2Heal’s proprietary Alakin Platform, a versatile care pathway builder. The platform will support the My Health Friend mobile health application, available in English, French, and Italian, breaking down language barriers and ensuring accessibility for a wide demographic.

This innovative application empowers users with personalized digital rehabilitation programs tailored to their specific needs, enhancing their well-being. Additionally, the Alakin clinical dashboard enables healthcare teams to remotely monitor patients, maintaining a high standard of care regardless of geographical distance.

The trial’s primary objectives include gathering data on user satisfaction and usage levels, with a focus on the general population across the transalpine territories of France and Italy. The trial will encompass 1000-1500 individuals over an 18-month period, ensuring robust and comprehensive results. Furthermore, the trial aims to assess the impact of the application on participants’ well-being and quality of life over a 6-month period.

This collaboration between Tech2Heal, French and Italian University Hospitals, and the European Commission represents a significant step forward in leveraging technology for improved healthcare accessibility and outcomes, particularly in regions with limited access to traditional healthcare services. The “My Health Friend” project is poised to make a lasting impact on preventative healthcare practices.

View Original Release: https://www.accesswire.com/794106/aiml-innovations-incs-subsidiary-chosen-as-the-digital-technology-provider-for-an-international-clinical-study-funded-by-european-commission

Predictmedix AI: Leading the Charge in Sustainable Healthcare and Workplace Safety

Posted by Brittany McNabb at 4:43 PM on Tuesday, October 10th, 2023

In an era where sustainability has become a paramount concern for businesses across industries, one area that often takes precedence is healthcare and workplace safety. Predictmedix AI, a Toronto-based health tech company, is not only redefining the landscape of healthcare but is also at the forefront of creating sustainable, cutting-edge solutions for the industry.

Sustainability: More Than Environmental Concerns

While sustainability is frequently associated with environmental initiatives, it extends far beyond that. In the healthcare sector, sustainability encompasses optimizing resources, reducing waste, enhancing efficiency, and most importantly, improving patient care. Predictmedix AI embraces this comprehensive view of sustainability, aiming to revolutionize how we approach healthcare and workplace safety.

Contactless Innovation: A Sustainable Approach

One of the key tenets of Predictmedix AI’s innovation is its commitment to contactless solutions. The company’s Safe Entry Stations utilize advanced AI and multispectral imaging to conduct non-invasive screenings. This approach not only enhances patient and employee safety but also minimizes the use of resources associated with traditional screening methods, such as disposable supplies and extensive cleaning protocols.

 Efficiency in Triage: Enhancing Patient Care

Predictmedix AI’s comprehensive triage solution is a game-changer for high-traffic hospitals, particularly in targeted Asian markets. By leveraging AI-driven technology, hospitals can significantly reduce the time patients spend in triage. This not only leads to better patient outcomes but also optimizes resource allocation, making healthcare delivery more sustainable and efficient.

 Strategic Partnerships: Fostering Innovation

Collaboration is a cornerstone of sustainability, and Predictmedix AI understands this well. Through strategic partnerships with institutions like the Indian Institute of Technology (IIT) and Max Healthcare, the company is fostering an environment of innovation. By combining expertise and resources, these collaborations are driving forward sustainable solutions that have the potential to revolutionize the healthcare landscape.

Global Impact: Deploying Technology Where it’s Needed

Predictmedix AI’s technology has been deployed at major events, forums, and clinical trials worldwide. This global reach signifies the company’s dedication to making a tangible impact on a global scale. By addressing healthcare and workplace safety challenges across different regions, Predictmedix AI is contributing to a more sustainable and resilient healthcare ecosystem. 

Market Potential: Sustained Growth in a Growing Industry

With an estimated market potential of $26.7 billion USD by 2027, Predictmedix AI is positioned for sustained growth. This not only highlights the financial viability of the company but also underscores the increasing recognition of the importance of sustainable healthcare solutions.

 A Sustainable Future with Predictmedix AI

As the healthcare and workplace safety landscape evolves, Predictmedix AI stands as a beacon of innovation and sustainability. By embracing contactless solutions, optimizing triage processes, fostering strategic collaborations, and making a global impact, the company is not only redefining healthcare but is also leading the charge in sustainable practices for the industry. With a market poised for substantial growth, Predictmedix AI is well on its way to creating a sustainable future for healthcare and workplace safety.

 

YOUR NEXT STEPS 

Visit $PMED HUB On AGORACOM: https://agoracom.com/ir/Predictmedixhttps 

Visit $PMED 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Predictmedix/profile

Visit $PMED Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Predictmedix/forums/discussion

Watch $PMED Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

 

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected] 

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions

Tech2Heal Secures Euro50,000 Funding Grant for Groundbreaking Elderly Autonomy Study

Posted by Brittany McNabb at 11:31 AM on Wednesday, October 4th, 2023

 

In a significant stride towards revolutionizing elderly care, Tech2Heal SAS, a subsidiary of AI/ML Innovations Inc., has been awarded a funding grant of Euro50,000. The grant comes as recognition for Tech2Heal’s pivotal role as the technological backbone in Europe’s largest study focused on the prevention of loss of autonomy in the elderly through personalized care pathways.

The groundbreaking study, spearheaded by the University Hospital of Nice in France, boasts a vast cohort of 30,000 elderly patients who will be closely monitored over a span of 5 years. Tech2Heal’s innovative Alakin Platform, selected for its exceptional capabilities, will serve as the linchpin in this monumental endeavor. The platform’s prowess lies in its ability to establish digital care pathways, gather comprehensive patient data, facilitate seamless communication, and integrate a diverse range of local and community services, all presented through an intuitive clinical dashboard.

What sets Alakin apart is its “no-code configurable platform,” allowing for rapid customization to meet the exacting demands of the University Hospital of Nice’s rigorous parameters. This adaptability is key in creating a sophisticated, large-scale clinical trial tailored precisely to the study’s unique requirements.

The initiative, led by Prof. Zory and Prof. Guerin, represents an amalgamation of health, innovation, and research. It aims to transform the Nice Côte d’Azur metropolitan area into a hub for groundbreaking experimentation and innovation in the realm of elderly autonomy. This participatory science project will engage 30,000 elderly participants over the next 5 years in personalized prevention programs while offering a platform for companies and researchers to trial innovative solutions.

The project’s core objectives include examining the accessibility, commitment, and effectiveness of autonomy prevention programs, investigating environmental influences, empowering the elderly in their care, and utilizing digital solutions for optimizing resource allocation. Through personalized prevention pathways, the project strives to forge a community of users who will play a vital role in its ongoing development and evaluation.

With an interdisciplinary structure and immediate societal impact, this project signifies a significant step towards redefining elderly care on a global scale. By integrating various research laboratories encompassing fields like public health, sociology, psychology, biology, and geography, the study promises to yield pioneering insights into enhancing the quality of life for the elderly.

View Original Release: https://aiml-innovations.com/wp-content/uploads/2023/10/AIML-News-Release-October-4-2023.pdf

Revolutionizing Healthcare: AI Scanner Promises Faster Assessments and Enhanced Safety

Posted by Brittany McNabb at 8:20 PM on Thursday, September 14th, 2023

 

In the realm of healthcare technology, a remarkable innovation is poised to transform patient care and safety. Predictmedix AI, a Toronto-based health tech company, has unveiled an AI-powered scanner that not only accelerates assessment times in hospitals but also plays a pivotal role in maintaining a drug-free environment by detecting cannabis. Let’s delve into how this groundbreaking technology is set to reshape healthcare practices.

Swift Assessments for Faster Care

Getting all the vital signs needed for patient diagnosis has traditionally been a time-consuming process. Predictmedix AI’s Safe Entry Station, an AI-powered scanner, is changing the game. This device can swiftly monitor vital signs, including heart rate and respiration rates, and even detect alcohol or cannabis intoxication. What sets it apart is its ability to provide this data in a matter of seconds, without invasive procedures or blood samples.

Redefining Triage Efficiency

For patients who spend hours in emergency rooms, a technology capable of significantly reducing triage times is a game-changer. Predictmedix AI’s scanner can shorten this process from up to an hour to less than 20 seconds. It achieves this by capturing vitals in a completely non-invasive, contactless manner. The results seamlessly integrate into the hospital’s medical system, enhancing overall efficiency.

Enhanced Safety with Cannabis Detection

Beyond rapid assessments, the AI scanner has an additional, unique capability: it can detect cannabis on individuals entering healthcare facilities. In regions where cannabis use is regulated or prohibited within healthcare premises, this feature ensures compliance and enhances security.

How It Works

The Safe Entry Station is equipped with multi-spectral cameras that analyze different wavelengths and a host of sensors. An edge computing unit, a powerful computer, processes this data on-site. Proprietary technology allows these cameras to analyze subtle changes in blood flow patterns, converting them into essential data such as blood pressure, heart rate, and the presence of alcohol or cannabis. Currently, it covers about 18 different parameters with an accuracy rate of over 90 percent.

Global Impact

Predictmedix AI has deployed its AI scanner in hospitals in India and Indonesia, with major sporting events in the U.S. also benefiting from this technology. The focus is on regions where a high patient flow necessitates swift vital sign measurements. The data collected is anonymized and used to train the algorithm, ensuring privacy and data security.

Affordable Accessibility

The business model for this AI scanner is a lease model. For a monthly fee of $2,000 to $4,000, users can have unlimited access to the technology. This affordability, coupled with its high accuracy, makes it an attractive option for healthcare providers and employers alike.

Augmenting, Not Replacing

The AI scanner isn’t meant to replace the human triage process but rather augment it. When it comes to measuring impairment, it provides valuable information. For vital sign measurements, its accuracy levels can potentially replace the entire process of manually measuring vitals.

As healthcare technology continues to evolve, innovations like Predictmedix AI’s AI scanner are leading the way towards more efficient, secure, and patient-centric care. This technology has the potential to redefine healthcare practices on a global scale, ultimately benefiting both patients and healthcare providers.

YOUR NEXT STEPS

Visit $PMED HUB On AGORACOM: https://agoracom.com/ir/Predictmedixhttps 

Visit $PMED 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Predictmedix/profile

Visit $PMED Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/Predictmedix/forums/discussion

Watch $PMED Videos On AGORACOM YouTube Channel:

https://www.youtube.com/feed/library

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visit  https://agoracom.com/terms-and-conditions

VIDEO – CEO’s $1 Million $FOBI Investment YTD Bolsters Confidence Following Remarkable Q3 Revenue and Q4 Outlook

Posted by AGORACOM-JC at 4:45 PM on Thursday, June 15th, 2023

Fobi AI Inc. (FOBI:TSXV) (FOBIF:OTCQB) has released a mid-year corporate update highlighting several significant initiatives and achievements.

Insider Buying and Warrant Exercises: Fobi has received over $1 million in insider buying and $300,000 in recent warrant exercises, demonstrating strong shareholder confidence in the company’s growth strategies. CEO Rob Anson personally invested over $1 million in the company year-to-date.

Record Q3 Revenues and Guidance: Fobi reported record Q3 2023 revenues of $1,255,093, a 298% year-over-year increase and a 151% sequential increase. The company’s guidance for Q4 2023 indicates confidence in hitting revenue targets.

M&A Success and Growth: Fobi’s strategic M&A activities have contributed to its record revenue. The acquisition of Passworks and the appointment of Colby McKenzie as Chief Revenue Officer are expected to accelerate growth and drive further acquisitions in the second half of 2023.

Strengthening Senior Management Team: Fobi welcomed Jason Tong as the new CFO to support its expanding team and evolving business trajectory. David Nicholls, a former Anheuser-Busch InBev executive, joined as VP of Liquor Beverage, enhancing Fobi’s senior management team and liquor beverage strategy.

Largest Recorded Revenue Deal: Fobi signed a $10 million licensing agreement with BevWorks Brands, the company’s largest recorded revenue deal. Fobi’s technology solutions will support BevWorks’ growth strategy in consolidating independent beverage manufacturers.

Wallet Pass Success and Enterprise Opportunities: Fobi’s wallet pass technologies, particularly through its subsidiaries Passcreator and Passworks, have driven revenue growth. The company is expanding beyond its traditional DIY-focused platform and seeing increased interest from larger-scale enterprise customers.

Qples Achievements: Qples, a subsidiary of Fobi, has seen significant growth in providing in-store mobile advertising solutions and digital media solutions. The launch of AI-8112 Universal Digital Coupons and the increase in client growth have been notable milestones.

Global Brand Exposure: Fobi gained significant brand exposure during the RBC Canadian Open, thanks to an epic finish and “incident” involving Fobi partner Adam Hadwin.

Overall, the mid-year update highlights Fobi’s financial success, M&A activities, strategic appointments, and global brand exposure, showcasing the company’s progress and growth in the AI and digital transformation space.

Now sit back, relax and watch this powerful interview with $FOBI CEO Rob Anson.

 

VIDEO – Fobi AI Year In Review – A Must See 1-Hour Jam Session

Posted by AGORACOM-JC at 4:24 PM on Thursday, December 30th, 2021
Fobi AI Inc.

FOBI AI is a global leader in digital wallet pass technology that delivers real-time data analytics and engagement through artificial intelligence to drive customer activation and engagement in stores, stadiums, arenas, hotels and other large venues around the world.  

More than just lip service, FOBI AI is firing on all cylinders. Here are just some of the highlights from December:

Some excerpts from CEO Rob Anson:

  • “Big names out of the gate in Q1”
  • “Plenty Wow I didn’t see that coming moments”

Sit back, relax and watch this power Fobi AI Year In Review.

VIDEO – Fobi To Acquire Portugal Based Digital Wallet And Mobile Marketing Company, Brings Tier-1 Clients and Immediate Revenue

Posted by AGORACOM-JC at 5:52 PM on Wednesday, December 8th, 2021
Whatsapp image 2021 06 01 at 12.42.51 pm

FOBI AI is a global leader in digital wallet pass technology that delivers real-time data analytics and engagement through artificial intelligence to drive customer activation and engagement in stores, stadiums, arenas, hotels and other large venues around the world.  

More than just lip service, these are just a sample of the major milestones reached by $FOBI as of the end of November:

  • 293% Increase In First Quarter Revenue 
  • Signed Agreement With Caddle, Canada’s Largest Mobile-First Insights Marketplace App To Target And Engage CPG Brands and Grocery Retailers
  • Signed Deal to Provide Digital Vaccination and Testing Verification Solution for Sammy Hagar’s Sold Out Shows at The STRAT Hotel, Casino & SkyPod in Las Vegas
  • Signed CheckVax(TM) Deal With the University of Nevada, Las Vegas for Men’s and Women’s NCAA Basketball Games
  • Closed Acquisition of PassWallet
  • …. and so much more

The company released it’s Q1 (ending Sept 30) results with a 293% increase in first quarter revenue.

  • Revenue increased substantially from $147,533 in Q4 to $580,317 in Q1.

But wait, that’s not all…

Fobi Announced Signing Of Amazon Fulfillment And Business Seller Agreement.

By joining Amazon Business, Fobi immediately reaches over 5 million business customers in nine countries: a network that Fobi is very proud to now be included in. Fobi will now generate additional revenue through hardware, products and services sold on Amazon Business.

And if that is not enough…

The Company signed LOI To Acquire Passworks, A Portugal Based Leading European Digital Wallet And Mobile Marketing Company With Tier-1 Global Clients

Rob Anson, Fobi CEO stated : “Acquiring Passworks will not only enable us to further accelerate our business strategy as we consolidate the wallet pass industry, but it will also provide us with direct and immediate access to very valuable customers, with additional operational capacity and provide further immediate revenue. This strategic acquisition of Passworks represents another key step for us in terms of achieving our goal of becoming a global mobile Wallet pass leader.”

Sit back, relax and watch this powerful interview with CEO Rob Anson.